Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
Clover Biopharmaceuticals announced promising results from its Phase I trial of the RSV vaccine candidate SCB-1019, demonstrating comparable immunogenicity to GSK’s AREXVY while showing significantly lower adverse event rates. The vaccine, based on Clover’s Trimer-Tag technology, holds potential for broader immune response and better tolerability, paving the way for further trials in 2025. This development could enhance Clover’s position in the competitive vaccine market, attracting keen interest from investors and market watchers.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
